 |
SK Bioscience (photo = SK Bioscience homepage) |
[Alpha Biz= Reporter Kim Minyoung] On the 27th, SK Bioscience announced that it will acquire IDT Biologika GmbH, a German company specializing in vaccine and biological product contract manufacturing (CMO).
IDT Biologika is a leading CMO company in Germany, with experience in handling COVID-19 vaccine contracts for J&J, Janssen, and AstraZeneca. Additionally, the company has a diverse track record, including CMO contracts with domestic botulinum toxin companies.
SK Bioscience has decided to acquire a 60.6% stake in the company for 318.6 billion KRW. With this acquisition, SK Bioscience aims to enhance its corporate value.
Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)
